StockData

BioAge Labs vs Palatin Technologies

BIOA and PTN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BIOA and PTN compare

BioAge Labs is the larger company, worth 22 times as much as Palatin Technologies ($240M against $10.9M).

BioAge Labs scores higher on the StockData Score (8 against 6 for Palatin Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBIOAPTN
Size and price
Market cap$240M$10.9M
Share price$5.22$6.13
Change, 1 year−32.4%−43.3%
Change, 5 years–−99.1%
Beta (5Y)2.40−0.07
Employees6225
StockData Score
Total score8 (better)6
Valuation score11
Growth score11
Performance score1 (better)0
Health score5 (better)4
Dividend score00
Valuation
P/S23.1×–
P/B0.6× (better)1.6×
FCF yield−36.8% (better)−125%
Growth
Revenue growth (TTM)168%–
Profitability
Operating margin−1026%–
Net margin−912%–
FCF margin−851%–
Return on equity−28.2% (better)−878%
Return on invested capital−283%–
Financial health
Debt / equity0.000.00
Interest coverage−378.2× (better)−1288.8×
Current ratio17.19 (better)4.61
Altman Z-score5.27 (better)−75.67
Piotroski F-score44
Dividends and buybacks
Buyback yield–−155%
Shareholder yield0.00% (better)−155%
Ownership
Held by institutions82.2%38.5%
Held by insiders21.9%20.6%
Insider net buying, 12 months−$7.8M−$9.5K (better)
Short interest, % of float10.4%20.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.